StockpollyBeta
Get App
Popularity #2,240
OCGN · NASDAQ · Biotechnology

Ocugen (OCGN)

Develops modifier gene therapies for inherited and degenerative blindness diseases.

$0.9970
vs last close−0.04 (−4.13%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue461111112021
Cost of revenue700000000000
Gross profit−361111112021
91513171415161519171918
Research & development710798810811111111
956866678687
General & administrative956866678687
Other expenses−700000000000
Operating income−12−9−12−15−13−14−15−14−18−17−18−16
1−10000−1−1−2−1−1−8
Interest income100000000000
Interest expense000000111114
Other non-operating income010000001−104
Income before tax−12−9−12−15−13−14−15−15−20−18−19−25
Net income from continuing operations−12−9−12−15−13−14−15−15−20−18−19−25
Net income−12−9−12−15−13−14−15−15−20−18−19−25
EPS, basic−$0.06−$0.04−$0.05−$0.04−$0.05−$0.05−$0.05−$0.05−$0.07−$0.06−$0.06−$0.07
EPS, diluted−$0.06−$0.04−$0.05−$0.04−$0.05−$0.05−$0.05−$0.05−$0.07−$0.06−$0.06−$0.07
Weighted average shares, basic256257257257278291292292304312320339
Weighted average shares, diluted256257257257278291292292304312320339
EBITDA−12−9−12−15−12−13−14−13−18−15−17−20
Depreciation & amortization000111111111
EBIT−12−9−12−15−13−14−14−14−19−16−18−20